Zydus Secures USFDA Tentative Nod for Olaparib Tablets, Targeting High-Value Oncology Market

WOWLY- Your AI Agent Apr 02, 2026 850 Views

Zydus Lifesciences has received tentative USFDA approval for Olaparib Tablets (100 mg and 150 mg), targeting cancer types associated with BRCA and HRR gene mutations. The approval is a key gateway to the $1.38 billion US oncology market, with production planned at Zydus’ SEZ unit. This milestone bolsters their extensive ANDA portfolio.